Search

Your search keyword '"Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse)"' showing total 9 results
Start Over Author "Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse)"
9 results on '"Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse)"'

1. Evolution of Major Amputation Risk in Patients Hospitalized in France for Critical Limb Ischemia: The COPART Registry

Author

Alessandra Bura-Rivière, Emmanuel Messas, Victor Aboyans, François-Xavier Lapébie, Ileana Desormais, Marion Mangin, Carine Boulon, P. Lacroix, Alice Coudene, Joël Constans, Valerie Aurillac, Service des Maladies Cardiaques et Vasculaires [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de Médecine Vasculaire [CHU Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Département d'endocrinologie - Bordeaux 2, Université Bordeaux Segalen - Bordeaux 2, Service de cardiologie [CHU Limoges], Service d'hypertension artérielle et médecine vasculaire, Hôpital Européen Georges Pompidou [APHP] (HEGP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)

Subjects
Male, critical limb ischemia, medicine.medical_specialty, Time Factors, Multivariate analysis, Statin, medicine.drug_class, Critical Illness, medicine.medical_treatment, Disease, 030204 cardiovascular system & hematology, peripheral artery disease, Revascularization, Risk Assessment, Amputation, Surgical, Peripheral Arterial Disease, 03 medical and health sciences, Cohorte des Patients ARTeriopathes, 0302 clinical medicine, Ischemia, Risk Factors, Internal medicine, Angioplasty, medicine, Humans, Registries, 030212 general & internal medicine, major amputation, Aged, Aged, 80 and over, business.industry, Endovascular Procedures, Critical limb ischemia, Odds ratio, Middle Aged, Limb Salvage, 3. Good health, Hospitalization, Treatment Outcome, Cohort, Female, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, prognosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Vascular Surgical Procedures
Abstract

International audience; Over the past decade, improvements in medical treatment and revascularization techniques have been beneficial for patients with peripheral artery disease in the late stage of critical limb ischemia (CLI). We evaluated the putative reduction in the number of major amputees in the Cohorte des Patients ARTeriopathes (COPART) cohort over time. Patients were selected from this multicenter cohort, from 2006 to 2016, for CLI according to Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease II criteria. Patients included before and after 2011 were compared. Patients were followed for 1 year. Primary outcome was the rate of major amputations. Secondary outcomes were minor amputations, deaths from all causes, cardiovascular deaths; 989 patients were included, 489 before 2011 and 450 after 2011. There was a significant decrease in rates of major amputation after 2011 (17% vs 25%), confirmed in multivariate analysis (odds ratio [OR]: 1.5 [1.1-2.2]), an increase in revascularization, particularly distal angioplasty (OR: 2.7 [1.7-4.4]) and increased statin intake (OR: 1.6 [1.1-2.1]). For secondary outcomes, there was no significant difference. Limb prognosis of CLI patients has improved over the past decade, possibly due to more revascularizations, particularly distal ones, and increased statin use.

Published
2020

2. High‐dose chemotherapy followed by autologous stem cell rescue in Wilms tumors: French report on toxicity and efficacy

Author

Isabelle Pellier, Hélène Sudour-Bonnange, Marie-Dominique Tabone, Claudia Pasqualini, Christophe Bergeron, Gudrun Scheleirmacher, Frédérique Dijoud, Aurore Coulomb-L'Hermine, Xavier Muracciole, Anne Notz-Carrere, Claire Freycon, Magali Morelle, Cécile Boulanger, Manon Delafoy, Arnauld Verschuur, Sabine Irtan, Estelle Thebaud, Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy], Institut Gustave Roussy (IGR), Hôpital de la Timone [CHU - APHM] (TIMONE), Institut Curie [Paris], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Méthodes computationnelles pour la prise en charge thérapeutique en oncologie : Optimisation des stratégies par modélisation mécaniste et statistique (COMPO), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de radiothérapie - [Hôpital de la Timone - Hôpital Nord - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE)- Hôpital Nord [CHU - APHM], Hospices Civils de Lyon (HCL), Centre Léon Bérard [Lyon], Service d'Hématologie pédiatrique, Hôpital de la Timone, Marseille, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Département d'oncologie pédiatrique [Institut Curie, Paris], Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité d'oncologie pédiatrique [Centre Oscar Lambret, Lille], Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER, Service d'oncologie pédiatrique [CHU Nantes], Service d'Onco-Hématologie Pédiatrique [CHU Grenoble], Service d'Hémato-oncologie Pédiatrique [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Service d'Hématologie et Oncologie pédiatriques [CHRU Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Service d'Immunologie Hématologie et Oncologie pédiatriques [CHU Angers], PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de chirurgie viscérale pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Service de pathologie [CHU Trousseau], Unité de Biostatistiques [Lyon], Centre Léon-Bérard : Centre de lutte contre le cancer de Lyon et Rhône-Alpes, and Département d'oncologie pédiatrique [Centre Léon Bérard, Lyon]

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Autologous Stem Cell Rescue, Adolescent, medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Transplantation, Autologous, Wilms Tumor, Young Adult, 03 medical and health sciences, High dose chemotherapy, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Young adult, Child, ComputingMilieux_MISCELLANEOUS, Retrospective Studies, Chemotherapy, business.industry, Stem Cells, Hematopoietic Stem Cell Transplantation, Wilms' tumor, Hematology, medicine.disease, Combined Modality Therapy, Kidney Neoplasms, 3. Good health, Respiratory failure, Child, Preschool, 030220 oncology & carcinogenesis, Pediatrics, Perinatology and Child Health, Toxicity, Cohort, Female, business, 030215 immunology
Abstract

International audience; BackgroundHeterogeneous data have been reported on high-dose chemotherapy (HDCT) with autologous stem cell rescue (ASCR) in Wilms tumors (WTs). We aimed to define its safety and efficacy in the French cohort, and to compare this management to current international recommendations.MethodsData prospectively collected from children, adolescents, and young adults with WT treated with HDCT/ASCR between 2000 and 2016 in French centers were retrospectively analyzed. Toxicity was reported according to CTCAE v4.03.ResultsFifty-four patients received HDCT/ASCR (first line, n = 13; recurrence, n = 41). Their median age at the time of ASCR was 5.3 years (range 2.2–21.6). Main nonhematological acute grades 3–4 toxicities were digestive and renal. No significant difference of toxicity rate was observed among HDCT regimens and schedules. Two patients died shortly after ASCR (renal and multiorgan failure), and one heavily pretreated patient died of late respiratory failure. The selection criteria applied to define those patients eligible for HDCT/ASCR retrospectively matched to those currently used in the International Society of Pediatric Oncology (SIOP) UMBRELLA protocol for 38 patients, with encouraging survival rates compared to published data. The objective response rate to HDCT was 21%, with a disease control rate after HDCT of 85%. After a median follow-up of 7 years, the 5-year event-free survival (EFS) and overall survival (OS) were 54% (95% CI: 32%–76%) and 62% (95% CI: 31%–82%) for frontline patients, and 57% (95% CI: 39%–71%) and 69% (95% CI: 52%–81%) at recurrence.ConclusionHDCT was feasible and showed encouraging results in well-defined settings. Data from the current prospective protocol will help to better evaluate HDCT impact on survival.

Published
2021

3. The effect of camelina oil on vascular function in essential hypertensive patients with metabolic syndrome

Author

Bellien, Jeremy, Bozec, Erwan, Bounoure, Frédéric, Khettab, Hakim, Malloizel-Delaunay, Julie, Skiba, Mohamed, Iacob, Michèle, Donnadieu, Nathalie, Coquard, Aude, Morio, Béatrice, Laillet, Brigitte, Rigaudière, Jean-Paul, Chardigny, Jean-Michel, Monteil, Christelle, Vendeville, Cathy, Mercier, Alain, Cailleux, Anne-Françoise, Blanchard, Anne, Amar, Jacques, Fezeu, Léopold, Pannier, Bruno, Bura-Rivière, Alessandra, Boutouyrie, Pierre, Joannidès, Robinson, Service de pharmacologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Centre d'Investigation Clinique [CHU Rouen] (CIC Rouen), Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Différenciation et communication neuronale et neuroendocrine (DC2N), Service de Pharmacologie, AP-HP, HEGP, Service de Médecine Vasculaire [CHU Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Pharmacie [CHU Rouen], Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Clermont Auvergne, CRNH Auvergne, UFR Santé, Médecine et Biologie Humaine (UFR SMBH), Université Sorbonne Paris Nord, Centre d'Investigation Clinique (CIC)-INSERM 1404, CIC - HEGP (CIC 1418), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Department of Arterial Hypertension, Toulouse University III, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Department of Nephrology, Centre Hospitalier F.H. Manhès, Université de Paris, Service de Pharmacologie, INSERM U970, équipe 7, Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service de pharmacie [CHU HEGP], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Recherche en Nutrition Humaine Auvergne [CHU Clermont-Ferrand] (CRNH A), Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Unité de Nutrition Humaine (UNH), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Service d'hypertension artérielle et thérapeutique [CHU Toulouse] (HTA et thérapeutique), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Néphrologie [CH Manhès, Fleury-Mérogis], Centre Hospitalier Manhès [Fleury-Mérogis], Biologie et pharmacologie de l'insuffisence cardiaque = Cellular, Molecular and Physiological Mechanisms of Heart Failure, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Hôpital Européen Georges Pompidou [APHP] (HEGP)

Subjects
Pathologic, Cyclodextrins, Eicosapentaenoic acid, Camelina oil, Insulin resistance, Vascular function, Metabolic syndrome, Dilatation, Essential hypertension, C-reactive protein, Cardiovascular system, Plasma, Fluid flow, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Metabolic syndrome x, Hypertension, Lipds, Thiobarbituric acid reactive substances, Endothelium, Alpha-linolenic acid
Abstract

International audience; Background The effects of a dietary supplementation with the vegetable omega-3 α-linolenic acid (ALA) on cardiovascular homeostasis are unclear. In this context, it would be interesting to assess the effects of camelina oil. Objective This study aimed to assess the cardiovascular and metabolic effects of camelina oil in hypertensive patients with metabolic syndrome. Methods In a double-blind placebo-controlled randomized study, treated essential hypertensive patients with metabolic syndrome received during 6 months either cyclodextrin-complexed camelina oil containing ≈ 1.5 g ALA/day (n = 40), or an isocaloric placebo (n = 41), consisting in the same quantity of cyclodextrins and wheat starch. Anthropometric data, plasma lipids, glycemia, insulinemia, creatininemia, thiobarbituric acid reactive substances, high-sensitivity C-reactive protein, and n-3, n-6 and n-9 fatty acids in erythrocyte membranes were measured. Peripheral and central blood pressures, arterial stiffness, carotid intima-media thickness and brachial artery endothelium-dependent flow-mediated dilatation and endothelium-independent dilatation were assessed. Results Compared to placebo, camelina oil increased ALA (mean ± SD: 0 ± 0.04 vs. 0.08 ± 0.06%, P

Published
2021

4. ISAba1-dependent overexpression of eptA in clinical strains of Acinetobacter baumannii resistant to colistin

Author

Anaïs Potron, Marlène Amara, Laurent Cavalié, Benoît Valot, Rémy A. Bonnin, Laurent Dortet, Florence Reibel, Christine Bernard, Patrick Plésiat, Gerald Larrouy-Maumus, Laurence Parmeland, Jean-Baptiste Vuillemenot, Maxime Bour, Pauline Triponney, Hélène Puja, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier de Versailles (CHV), Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Grand Hôpital de l'Est Parisien, Centre hospitalier Saint Joseph - Saint Luc [Lyon], Groupe Hospitalier Nord Essonne [Longjumeau], Imperial College London, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Centre Hospitalier de Versailles André Mignot (CHV)

Subjects
Acinetobacter baumannii, Male, Microbiology (medical), Operon, Biology, law.invention, Microbiology, 03 medical and health sciences, Bacterial Proteins, Start codon, law, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Drug Resistance, Bacterial, medicine, Humans, Pharmacology (medical), Gene, ComputingMilieux_MISCELLANEOUS, Polymerase chain reaction, Aged, 030304 developmental biology, Aged, 80 and over, Pharmacology, Whole genome sequencing, 0303 health sciences, Whole Genome Sequencing, Colistin, 030306 microbiology, Middle Aged, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Anti-Bacterial Agents, Infectious Diseases, Multilocus sequence typing, Female, Acinetobacter Infections, Transcription Factors, medicine.drug
Abstract

BackgroundColistin resistance in Acinetobacter baumannii often results from mutational activation of the two-component system PmrAB and subsequent addition of phospho-ethanolamine (pEtN) to lipooligosaccharide by up-regulated pEtN transferase PmrC.ObjectivesTo characterize mechanisms of colistin resistance independent of PmrCAB in A. baumannii.MethodsTwenty-seven colistin-resistant A. baumannii were collected from 2012 to 2018. Analysis of operon pmrCAB was performed by PCR and sequencing. Seven strains were investigated further by WGS and whole-genome MLST (wgMLST).ResultsSeven out of the 27 selected isolates were found to overexpress eptA, a gene homologous to pmrC, likely as a consequence of upstream insertion of an ISAba1 element. Insertion sites of ISAba1 were mapped 13, 18 and 156 bp ahead of the start codon of eptA in five strains, one strain and one strain, respectively. The finding that the isolates did not cluster together when compared by wgMLST analysis supports the notion that distinct insertion events occurred in close, but different, genetic backgrounds.ConclusionsActivation of eptA and subsequent addition of pEtN to the cell surface represents a novel mechanism of resistance to colistin in A. baumannii.

Published
2019

5. Restoring Endothelial Function by Targeting Desert Hedgehog Downstream of Klf2 Improves Critical Limb Ischemia in Adults

Author

Marie-Ange Renault, Caroline Caradu, Candice Chapouly, Pierre-Louis Hollier, Sarah Guimbal, Alessandra Bura-Rivière, Thierry Couffinhal, Mathilde Dubois, Eric Ducasse, Alain-Pierre Gadeau, Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Vasculaire [CHU Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Centre de recherche Cardio-Thoracique de Bordeaux [Bordeaux] (CRCTB), Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), This study was sponsored by the Toulouse University Hospital Centre and supported by a grant from the French Ministry of Health (Interregional Clinical Research Hospital Program PHRC-I 2009 N°RCB: 2009-A00889-48), the Société de Chirurgie Vasculaire et Endovasculaire de langue française, and the Fondation de France, Appels d’Offre Recherche sur les maladies Cardiovasculaires 2013 and 2018. Additionally, this study was co-funded by the Institut National de la Santé et de la Recherche Médicale and by the University of Bordeaux., Université de Bordeaux (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Boullé, Christelle

Subjects
Male, 0301 basic medicine, Physiology, 030204 cardiovascular system & hematology, 0302 clinical medicine, Ischemia, therapeutics, Medicine, Cells, Cultured, Mice, Knockout, Cyclohexylamines, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Hindlimb, 3. Good health, Cell biology, Autocrine Communication, KLF2, Cytokines, Inflammation Mediators, medicine.symptom, Cardiology and Cardiovascular Medicine, Signal Transduction, Critical Illness, Upstream and downstream (transduction), Kruppel-Like Transcription Factors, Neovascularization, Physiologic, Inflammation, Thiophenes, Capillary Permeability, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Downstream (manufacturing), peripheral arterial disease, Human Umbilical Vein Endothelial Cells, Animals, Humans, Hedgehog Proteins, Muscle, Skeletal, Desert hedgehog, business.industry, hedgehogs, Endothelial Cells, Critical limb ischemia, Mice, Inbred C57BL, Disease Models, Animal, 030104 developmental biology, Gene Expression Regulation, Article RECHERCHE, inflammation, Regional Blood Flow, Stress, Mechanical, business, Function (biology)
Abstract

Rationale: Klf (kruppel-like factor) 2 is critical to establish and maintain endothelial integrity. Objective: Therefore, determining upstream and downstream mediators of Klf2 would lead to alternative therapeutic targets in cardiovascular disease management. Methods and Results: Here we identify Dhh (desert hedgehog) as a downstream effector of Klf2, whose expression in endothelial cells (ECs) is upregulated by shear stress and decreased by inflammatory cytokines. Consequently, we show that Dhh knockdown in ECs promotes endothelial permeability and EC activation and that Dhh agonist prevents TNF-α (tumor necrosis factor alpha) or glucose-induced EC dysfunction. Moreover, we demonstrate that human critical limb ischemia, a pathological condition linked to diabetes mellitus and inflammation, is associated to major EC dysfunction. By recreating a complex model of critical limb ischemia in diabetic mice, we found that Dhh-signaling agonist significantly improved EC function without promoting angiogenesis, which subsequently improved muscle perfusion. Conclusion: Restoring EC function leads to significant critical limb ischemia recovery. Dhh appears to be a promising target, downstream of Klf2, to prevent the endothelial dysfunction involved in ischemic vascular diseases.

Published
2018

6. Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease

Author

Fouad Madhi, Isabelle Koné-Paut, Stéphanie Tellier, Martha Darce Bello, Ulrich Meinzer, Maryam Piram, Franck Boralevi, Rolando Cimaz, Celine Piedvache, Sylvie Di Filippo, Pediatric Rheumatology [Le Kremlin-Bicêtre], Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [Le Kremlin-Bicêtre] (CeRéMAIA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Paediatric Rheumatology, Nephrology and Internal medicine [Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Hospices Civils de Lyon (HCL), Dermatology [Bordeaux], CHU Bordeaux [Bordeaux], Paediatrics [Créteil], Centre Hospitalier Intercommunal de Créteil (CHIC), Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases [Paris], Centre de référence des rhumatismes inflammatoires et maladies autoimmunes systémiques rares de l'enfant [Paris] (RAISE), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Milan, Clinical Research Unit [Le Kremlin-Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, The sponsor was Assistance Publique-Hôpitaux de Paris (Département de la Recherche Clinique et du Développement). The study was funded by a grant from Programme Hospitalier de Recherche Clinique-PHRC 2009 (French Ministry of Health) and the French Society of Rheumatology (SFR)., Bodescot, Myriam, Service Néphrologie, médecine interne et hypertension pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Università degli Studi di Milano = University of Milan (UNIMI)

Subjects
Male, Multivariate analysis, Vasculitis syndromes, Drug Resistance, lcsh:Medicine, Drug resistance, 030204 cardiovascular system & hematology, Pediatrics, Severity of Illness Index, 0302 clinical medicine, Risk Factors, Ethnicity, Medicine, Prospective Studies, Prospective cohort study, lcsh:Science, Child, education.field_of_study, Paediatric rheumatic diseases, Multidisciplinary, Immunoglobulins, Intravenous, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Child, Preschool, Female, France, Risk assessment, medicine.medical_specialty, Population, Mucocutaneous Lymph Node Syndrome, Risk Assessment, Sensitivity and Specificity, Article, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 030225 pediatrics, Internal medicine, Severity of illness, Humans, education, Retrospective Studies, business.industry, lcsh:R, Infant, Reproducibility of Results, Retrospective cohort study, medicine.disease, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Multivariate Analysis, Kawasaki disease, lcsh:Q, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business
Abstract

About 10–20% of patients with Kawasaki disease (KD) are unresponsive to intravenous immunoglobulin (IVIg) and are at increased risk of coronary artery abnormalities (CAAs). Early identification is critical to initiate aggressive therapies, but available scoring systems lack sensitivity in non-Japanese populations. We investigated the accuracy of 3 Japanese scoring systems and studied factors associated with IVIg unresponsiveness in a large multiethnic French population of children with KD to build a new scoring system. Children admitted for KD between 2011–2014 in 65 centers were enrolled. Factors associated with second line-treatment; i.e. unresponsiveness to initial IVIg treatment, were analyzed by multivariate regression analysis. The performance of our score and the Kobayashi, Egami and Sano scores were compared in our population and in ethnic subgroups. Overall, 465 children were reported by 84 physicians; 425 were classified with KD (55% European Caucasian, 12% North African/Middle Eastern, 10% African/Afro-Caribbean, 3% Asian and 11% mixed). Eighty patients (23%) needed second-line treatment. Japanese scores had poor performance in our whole population (sensitivity 14–61%). On multivariate regression analysis, predictors of secondary treatment after initial IVIG were hepatomegaly, ALT level ≥30 IU/L, lymphocyte count 3 and time to treatment

Published
2020

7. A fast UPLC–HILIC method for an accurate quantification of dendrogenin A in human tissues

Author

Regis Soules, Etienne Chatelut, Fabien Audouard-Combe, Marc Poirot, Ben Allal, Arnaud Rives, Sandrine Silvente-Poirot, Camille Franchet, Philippe de Medina, Emilie Huc-Claustre, Florence Dalenc, Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Equipe Labellisée par la Ligue Nationale contre le Cancer, LNCC, Waters S.A.S. [Saint-Quentin En Yvelines, France], Laboratoire de chimie de coordination (LCC), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius-Regaud (IUCO Toulouse), Institut Universitaire du Cancer Toulouse - Oncopôle (IUCT), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), M. Poirot and S. Silvente-Poirot's team was funded by the Institut National de la Santé et de la Recherche Médicale (INSERM), the Université de Toulouse III, the Institut National du Cancer (INCA, PRTKK15-118, PLBIO18-130), the Fondation Toulouse Cancer Santé (2017CS065), and the associations 'Céline' and 'Flo'., Equipe labellisée Ligue contre le Cancer, Affichem [Toulouse, France], Dendrogenix [Liège, Belgium], Institut Claudius Regaud, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Anatomie et cytologie pathologiques [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Poirot, Marc, CRLCC Institut Claudius Regaud, Pôle Institut Universitaire du Cancer - Oncopole [CHU Toulouse] (Pôle IUC - Oncopole), CHU Toulouse [Toulouse]-Oncopole de Toulouse, Service d'Anatomo-Pathologie [CHU Toulouse], Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), CHU Toulouse [Toulouse]-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), and Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)

Subjects
0301 basic medicine, Endocrinology, Diabetes and Metabolism, Metabolite, [SDV]Life Sciences [q-bio], Clinical Biochemistry, Breast Neoplasms, UPLC-MS, Mass spectrometry, Biochemistry, High-performance liquid chromatography, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Oxysterol, In vivo, Quantification, [SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology, Protein precipitation, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Breast, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Molecular Biology, [SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biochemistry [q-bio.BM], Chromatography, Hydrophilic interaction chromatography, Method development, Imidazoles, Cell Biology, In vitro, 3. Good health, [SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biomolecules [q-bio.BM], [SDV] Life Sciences [q-bio], 030104 developmental biology, Cholesterol, chemistry, Steroidal alkaloid, Dendrogenin B, 030220 oncology & carcinogenesis, Cancer cell, Dendrogenin A, Molecular Medicine, Female, Cholestanols, Chromatography, Liquid
Abstract

International audience; Dendrogenin A (DDA) is a newly-discovered steroidal alkaloid, which remains to date the first ever found in mammals. DDA is a cholesterol metabolites that induces cancer cell differentiation and death in vitro and in vivo, and thus behave like a tumor suppressor metabolite. Preliminary studies performed on 10 patients with estrogen receptor positive breast cancers (ER(+)BC) showed a strong decrease in DDA levels between normal matched tissue and tumors. This suggests that a deregulation on DDA metabolism is associated with breast carcinogenesis. To further investigate DDA metabolism on large cohorts of patients we have developed an ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS) procedure for the quantification of DDA in liquid and in solid tissues. This method enabled the identification of DDA analogues such as its geometric isomer C17 and dendrogenin B (C26) in human samples showing that other 5,6α-epoxycholesterol conjugation products with biogenic amines exist as endogenous metabolites . We report here the first complete method of quantification of DDA in liquid and solid tissues using hydrophilic interaction liquid chromatography (HILIC). Two different methods of extraction using either a Bligh and Dyer organic extraction or protein precipitation were successfully applied to quantify DDA in solid and liquid tissues. The protein precipitation method was the fastest. The fact that this method is automatable opens up possibilities to study DDA metabolism in large cohorts of patients.

Published
2019

8. Les évaluations économiques en population dans les prises en charge des cancers : évaluation des coûts des lymphomes et de la leucémie myéloïde chronique

Author

Mounié, Michael, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Université Paul Sabatier - Toulouse III, Laurent Molinier, Nicolas Savy, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), STAR, ABES, Unité d'Evaluation Médico-Economique du CHU de Toulouse (UEME), Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), Université Fédérale Toulouse Midi-Pyrénées, Embodiment, social ineQualities, lifecoUrse epidemiology, cancer and chronIc diseases, intervenTions, methodologY (Equipe 5 - EQUITY), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), LEASP - Laboratoire d'Epidémiologie et Analyses en santé publique, and Molinier Laurent & Savy Nicloas

Subjects
hematological malignancy, [STAT.AP]Statistics [stat]/Applications [stat.AP], Medico-administrative databases, Approche populationnelle, modeling, [SDV.CAN]Life Sciences [q-bio]/Cancer, Evaluation économique en santé, Malignant hemopathies, Economic evaluation, Bases de données médico-administratives, [SDV.CAN] Life Sciences [q-bio]/Cancer, Modélisation, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Modelisation, Real world evidences, Hémopathie maligne, real-world approach, approche populationnelle, Health economic
Abstract

The French health care system has difficulties to manage health expenditure, which places decision-makers in front of budgetary constraints making necessary to prioritize strategies in public health. In this context, Economic Evaluation and Health Economic Evaluation (HEE) help to an optimal allocation of resources. Cancers are particularly concern with this problem. These pathologies are a national health issue due to their high prevalence, mortality and the costly nature of its treatments. In addition, the large changes in the management of cancer pathologies and the increased resource they consume bring a major place to economic evaluation in this area. Hematological malignancies are directly concerned by these issues with significant therapeutic advances made in recent years, particularly in Chronic Myeloid Leukemia (CML), lymphoid leukemia, lymphoma and myeloma. HEEs for the management of cancer pathologies use generally data from Randomized Clinical Trials (RCTs). These studies are focused on a specific treatment related to strictly selected and over-controlled population. The population based approach using observational data is interesting because it allows the production of results reflecting actual practices. The recent ease access to the national health insurance databases offers interesting possibilities with regard to this issue. Nevertheless, without the methodological rigor of RCTs, the information contained in the databases could be called "imperfect". Therefore, the use of statistical modeling is essential in order to structure and improve understanding the information contained in the data. Various models exist and can be transposed to the economic evaluation of cancer management context. Knowledge of the underlying assumptions allows to use the most relevant when it's needed and to obtain results near to reality. Conducted as part of the CAPTOR (Cancer Pharmacology of Toulouse-Oncopole and Region) research program on anti-cancer drugs, this thesis aimed to describe and analyze the costs of lymphoma and CML in France. The work carried out the various expenditure items in the management of lymphomas according to pathologies considered. In addition, our works have allowed a first description of the costs of the management of CML in France, of these cost drivers and the variations due to the different treatments dispensed. This work highlights the potential and the importance of health insurance databases to realize economic evaluation of diseases in France using suitable models according to the different problematics met., Le système de soin français rencontre des difficultés de financement des dépenses de santé qui placent les décideurs face à des contraintes budgétaires rendant nécessaire la priorisation des stratégies en termes de santé publique. Dans un tel contexte, les évaluations économiques des stratégies médicales, et notamment les Evaluations Médico-Economiques (EME), peuvent aider à une allocation optimale des ressources. La cancérologie notamment n'échappe pas à cette problématique. Elle constitue un enjeu national en santé de par la forte prévalence, mortalité et le caractère onéreux de ses traitements. De plus, les constantes évolutions des prises en charges des pathologies cancéreuses, parallèlement aux moyens accrus qu'elles consomment, prodiguent une importance primordiale aux évaluations économiques dans ce domaine. Les hémopathies malignes sont directement concernées par ces questions avec des avancées thérapeutiques majeures réalisées ces dernières années notamment dans la Leucémie Myéloïde Chronique (LMC), la leucémie lymphoïde, les lymphomes et les myélomes. Les EME des prises en charge des pathologies cancéreuses sont généralement issues d'Essais Cliniques Randomisés (ECR) sur des populations sélectionnées, sur-contrôlées et centrées sur un traitement spécifique. L'approche en population basée sur des données d'observations est alors intéressante car elle permet la production de résultats reflétant les pratiques réelles. L'accès désormais facilité aux bases de données médico-administratives nationales du SNDS offre des possibilités intéressantes au regard de cet enjeu. Néanmoins, sans la rigueur méthodologique des ECR, l'information contenue dans les bases est dite "imparfaite", et le recours à la modélisation statistique est essentiel afin de structurer et d'appréhender au mieux l'information contenue dans les données. Différents modèles théoriques existent et peuvent être transposés aux problématiques des évaluations économiques des stratégies de soins des pathologies cancéreuses. La connaissance des hypothèses sous-jacentes à ces modèles permet l'usage des plus pertinents le cas échéant et ainsi l'obtention de résultats approchant au mieux la réalité. Réalisée dans le cadre du programme de recherche CAPTOR (Cancer Pharmacology of Toulouse-Oncopole and Region) sur les médicaments anti-cancéreux, cette thèse avait pour objectifs de décrire et d'analyser les coûts des lymphomes et de la LMC en France. Les travaux effectués ont permis de mettre en évidence les différents postes de dépenses dans la prise en charge des lymphomes selon les pathologies considérées et d'identifier où des économies potentielles peuvent être réalisées. De plus, les recherches mises en œuvre ont permis une première description des coûts de la prise en charge de la LMC en France, de ces inducteurs de coûts et des variations dues aux différents traitements dispensés. Ces travaux mettent en avant le potentiel et l'importance d'utiliser les bases du SNDS pour l'évaluation économique des pathologies en France tout en utilisant des modèles adaptés aux problématiques soulevées.

Published
2019

9. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction

Author

Sébastien Bommart, Emilie Passerieux, Ahmed Turki, Raul Juntas Morales, Gilles Carnac, Alexandra Belayew, Dalila Laoudj-Chenivesse, Sylvia Pietri, Karen Lambert, Joël Pincemail, Fabien Pillard, Gérald Hugon, Maurice Hayot, Eric Raynaud de Mauverger, Jacques Mercier, Yegor S. Vassetzky, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Toulouse (CHRU Toulouse), CHU, Liège, Institut de Chimie Radicalaire (ICR), Aix Marseille Université (AMU)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Service de Biologie Moléculaire, Université de Mons, Belgique, Interactions moléculaires et cancer (IMC (UMR 8126)), Signalisation, noyaux et innovations en cancérologie (UMR8126), Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut Gustave Roussy (IGR)-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut Gustave Roussy (IGR)-Université Paris-Sud - Paris 11 (UP11), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Pietri, Sylvia

Subjects
Male, MnSOD, Cu-SOD, DUX4, [SDV]Life Sciences [q-bio], Glutathione reductase, Mitochondria dysfunction, thiobarbituric acid-reactive substances, medicine.disease_cause, Biochemistry, Antioxidants, chemistry.chemical_compound, 0302 clinical medicine, Facioscapulohumeral muscular dystrophy, endurance limit time, double homebox 4 gene, Muscular dystrophy, ComputingMilieux_MISCELLANEOUS, 2 minute walking test n Correspondence to: INSERM, reactive oxygen species, 0303 health sciences, 2-MWT, Chemistry, T Lim, Autosomal dominant trait, ROS, oxidized glutathione, Muscular Dystrophy, Facioscapulohumeral, Mitochondria, [SDV] Life Sciences [q-bio], GR, medicine.anatomical_structure, Radical oxygen species, MVC, copper-zinc-dependent superoxide dismutase, Female, GSSG, musculoskeletal diseases, Adult, medicine.medical_specialty, 4-hydroxy-2-nonenal, TBARS, Lipofuscin, Facioscapulohumeral muscular dystrophy (FSHD), 03 medical and health sciences, Physiology (medical), Internal medicine, medicine, GSH, Humans, Facioscapulohumeral muscular dystrophy (FSHD) 4-Hydroxy-2-nonenal Thiobarbituric acid-reactive substances Lipofuscin Oxidative stress Protein oxidation Radical oxygen species Mitochondria dysfunction Antioxidants Abbreviations: FSHD, reduced glutathione, glutathione reductase, 030304 developmental biology, manganese-dependent superoxide dismutase, Skeletal muscle, facioscapulohumeral dystrophy, Glutathione, Bâtiment Crastes de Paulet, medicine.disease, Endocrinology, HNE, Oxidative stress, maximal voluntary contraction, Protein oxidation, 030217 neurology & neurosurgery, U1046
Abstract

Facioscapulohumeral muscular dystrophy (FSHD), the most frequent muscular dystrophy, is an autosomal dominant disease. In most individuals with FSHD, symptoms are restricted to muscles of the face, arms, legs, and trunk. FSHD is genetically linked to contractions of the D4Z4 repeat array causing activation of several genes. One of these maps in the repeat itself and expresses the DUX4 (the double homeobox 4) transcription factor causing a gene deregulation cascade. In addition, analyses of the RNA or protein expression profiles in muscle have indicated deregulations in the oxidative stress response. Since oxidative stress affects peripheral muscle function, we investigated mitochondrial function and oxidative stress in skeletal muscle biopsies and blood samples from patients with FSHD and age-matched healthy controls, and evaluated their association with physical performances. We show that specifically, oxidative stress (lipid peroxidation and protein carbonylation), oxidative damage (lipofuscin accumulation), and antioxidant enzymes (catalase, copper-zinc-dependent superoxide dismutase, and glutathione reductase) were higher in FSHD than in control muscles. FSHD muscles also presented abnormal mitochondrial function (decreased cytochrome c oxidase activity and reduced ATP synthesis). In addition, the ratio between reduced (GSH) and oxidized glutathione (GSSG) was strongly decreased in all FSHD blood samples as a consequence of GSSG accumulation. Patients with FSHD also had reduced systemic antioxidative response molecules, such as low levels of zinc (a SOD cofactor), selenium (a GPx cofactor involved in the elimination of lipid peroxides), and vitamin C. Half of them had a low ratio of gamma/alpha tocopherol and higher ferritin concentrations. Both systemic oxidative stress and mitochondrial dysfunction were correlated with functional muscle impairment. Mitochondrial ATP production was significantly correlated with both quadriceps endurance (T(LimQ)) and maximal voluntary contraction (MVC(Q)) values (rho=0.79, P=0.003; rho=0.62, P=0.05, respectively). The plasma concentration of oxidized glutathione was negatively correlated with the T(LimQ), MVC(Q) values, and the 2-min walk distance (MWT) values (rho=-0.60, P=0.03; rho=-0.56, P=0.04; rho=-0.93, P0.0001, respectively). Our data characterized oxidative stress in patients with FSHD and demonstrated a correlation with their peripheral skeletal muscle dysfunction. They suggest that antioxidants that might modulate or delay oxidative insult may be useful in maintaining FSHD muscle functions.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results